Literature DB >> 30314921

Rapid eye movement behavior disorder in drug-naïve patients with Parkinson's disease.

Hui Liu1, Ruwei Ou1, Qianqian Wei1, Yanbing Hou1, Bei Cao1, Bi Zhao1, Huifang Shang2.   

Abstract

The current study aimed to investigate the occurrence and clinical associations of rapid eye movement (REM) behavior disorder (RBD) in early-stage Parkinson's disease (PD) from a cohort of Chinese patients. 158 treatment-naive PD patients in total were enrolled in the study. Each patient was categorized as PD with or without RBD according to the Rapid Eye Movement Sleep Behavior Disorder Screening Questionnaire (RBDSQ). Of 158 patients, 31 PD patients (19.62%) reported RBD. PD patients with RBD showed higher Non-Motor Symptoms Scale (NMSS) score, higher Hamilton Depression Rating Scale (HAMD) score, higher Hamilton Anxiety Rating Scale (HAMA) score, higher Fatigue Severity Scale (FSS) score, higher PD Sleep Scale 2nd version (PDSS-2) score, lower Montreal Cognitive Assessment (MOCA) score and higher scores for the cognitions and communication domains from the PD Questionnaire-39 (PDQ-39). The stepwise binary logistic regression analysis showed that higher HAMA score (OR = 1.089, 95% CI = 1.010-1.174, P = 0.026), higher motor symptoms at night domain score from the PDSS-2 (OR = 1.389, 95% CI = 1.128-1.711, P = 0.002) and lower MOCA score (OR = 0.864, 95% CI = 0.757-0.986, P = 0.030) were correlated with RBD. This study found that RBD is not rare (19.62%) in Chinese drug-naïve PD patients and RBD has a great effect on quality of life. RBD in PD is related to cognitive dysfunction, anxiety and sleep disturbances.
Copyright © 2018. Published by Elsevier Ltd.

Entities:  

Keywords:  Non-motor symptoms; Parkinson’s disease; Rapid eye movement behavior disorder

Mesh:

Year:  2018        PMID: 30314921     DOI: 10.1016/j.jocn.2018.07.007

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  7 in total

Review 1.  Sleep Disorders and Cognitive Dysfunctions in Parkinson's Disease: A Meta-Analytic Study.

Authors:  Gianpaolo Maggi; Luigi Trojano; Paolo Barone; Gabriella Santangelo
Journal:  Neuropsychol Rev       Date:  2021-03-29       Impact factor: 7.444

2.  Increased rapid eye movement density in Chinese patients with Parkinson's disease and RBD.

Authors:  Jun Zhu; Liyu Lu; Min Zhong; Xu Jiang; Zhuang Wu; Jingde Dong; Yang Pan; Li Zhang
Journal:  Neurol Sci       Date:  2020-07-16       Impact factor: 3.307

3.  Prevalence and profile of nocturnal disturbances in Chinese patients with advanced-stage Parkinson's disease: a cross-sectional epidemiology study.

Authors:  Guiying He; Chun-Feng Liu; Qinyong Ye; Zhenguo Liu; Miao Jin; Huifang Shang; Ling Chen; Houzhen Tuo; Hong Jiang; Jifu Cai; Kalpesh Joshi; James Cooper; Lu Zi; Shengdi Chen
Journal:  BMC Neurol       Date:  2021-05-12       Impact factor: 2.474

4.  Sleep Disturbances and Associated Factors in Drug-Naïve Patients with Parkinson's Disease.

Authors:  Min Zhong; Xu Jiang; Sha Zhu; Ruxin Gu; Yu Bai; Hong He; Yang Pan; Pingyi Xu; Jun Yan; Li Zhang
Journal:  Neuropsychiatr Dis Treat       Date:  2021-12-03       Impact factor: 2.570

5.  Cerebrospinal Fluid TNF-α and Orexin in Patients With Parkinson's Disease and Rapid Eye Movement Sleep Behavior Disorder.

Authors:  Yuan Yuan; Yimeng Zhang; Yueyang Cheng; Yue Hou; Zhaoyang Huang; Jinghong Ma; Ning Li; Shuqin Zhan
Journal:  Front Neurol       Date:  2022-02-18       Impact factor: 4.003

6.  Blood neuroexosomal excitatory amino acid transporter-2 is associated with cognitive decline in Parkinson's disease with RBD.

Authors:  Bing Leng; Hairong Sun; Mengfan Li; Junwu Zhao; Xiaoxiao Liu; Ran Yao; Tengqun Shen; Zhenguang Li; Jinbiao Zhang
Journal:  Front Aging Neurosci       Date:  2022-08-23       Impact factor: 5.702

7.  Non-motor symptoms are associated with REM sleep behavior disorder in Parkinson's disease: a systematic review and meta-analysis.

Authors:  Dan Xie; Qiuyan Shen; Junying Zhou; Yanming Xu
Journal:  Neurol Sci       Date:  2020-10-06       Impact factor: 3.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.